de León-Cantú RE, Carrizales-Villarreal JACeballos-López AA, Gómez-Almaguer D

Idioma: Español
Referencias bibliográficas: 21
Paginas: 140-143
Archivo PDF: 72.71 Kb.

RESUMEN

La leucemia aguda promielocítica se distingue del resto de las leucemias mieloblásticas en la biología, clínica, pronóstico y tratamiento. Se reconocen tres grupos de riesgo. La frecuencia de infiltración al sistema nervioso central es baja. Se reporta una serie de cuatro casos con leucemia aguda promielocítica y recaída al sistema nervioso central. Tres pacientes son adultos y uno pediátrico. Dos pacientes son de alto riesgo, uno con riesgo intermedio y el otro con riesgo bajo. En la inducción a la remisión todos los pacientes se trataron con ácido holo-transretinoico y antraciclinas y se continuó con consolidaciones dependiendo riesgo. En uno de los pacientes se utilizó trióxido de arsénico y trasplante autólogo posterior a la recaída. Se revisa la bibliografía y se concluye que en pacientes con riesgo alto debe considerarse la profilaxis para leucemia meníngea.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Bae SH, Ryoo HM, Cho HS, Lee JL, et al. Meningeal relapse in a patient with acute promyelocytic leukemia: a case report and review of the literature. J Korean Med Sci 2004;19:311-314.

2. Kim SH, Yun J, Kim HJ, Kim CK, et al. Long-term survival in a patient with acute promyelocytic leukemia with isolated meningeal relapse. Korean J Hematol 2010;45:208-210.

3. Tallman MS, Altman JK. Curative strategies in acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program 2008;391-399.

4. Specchia G, Lo Coco F, Vignetti M, et al. Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. J Clin Oncol 2001;19:4023-4028.

5. Scheinemann K, Weitzman S, Hitzler J, Doyle J, Abla O. Isolated central nervous system relapse in childhood acute promyelocytic leukemia. J Pediatr Hematol Oncol 2008;30:160-162.

6. Akoz AG, Dagdas S, Ozet G, Ceran F, Yilmaz M. Isolated central nervous system relapse during cytologic and molecular hematologic remission in two patients with acute promyelocytic leukemia. Hematology 2007;12:419-422.

7. De Botton S, Sanz MA, Chevret S, et al. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia 2006;20:35-41.

8. Breccia M, Petti MC, Testi AM, et al. Ear involvement in acute promyelocytic leukemia at relapse: a disease-associated'sanctuary'? Leukemia 2002;16:1127-1130.

9. Marchetti M, Falanga A, Giovannelli S, et al. All-trans retinoic acid increases adhesion to endothelium of the human APML cell line NB4. Br J Haematol 1996;93:360-366.

10. Di Noto R, Lo Pardo C, Schiavone EM, et al. All-trans retinoic acid (ATRA) and the regulation of adhesion molecules in acute myeloid leukemia. Leuk Lymphoma 1996;21:201-209.

11. Patriarca F, Fili C, Geromin A, Sperotto A, et al. Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia. Eur J Haematol 2002;68:310-313.

12. Marra R, Stori S, Pagano L, et al. Central nervous system acute promyelocytic leukaemia: a report of three cases. Haematologia (Budap) 1989;22:195-199.

13. Kiguchi T, Yoshino Y, Yuan B , et al. Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia. Leuk Res 2010;34:403-405.

14. Helwig A, Klemm M, Schüttig R, et al. Arsenic-induced APL differentiation in cerebrospinal fluid. Leuk Res 2007;31:703-705.

15. Au WY, Tam S, Fong BM, Kwong YL. Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. Blood 2008;112:3587-3590.

16. Meloni G, Diverio D, Vignetti M, et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. Blood 1999;90:1321-1325.

17. Ferrara F, Finizio O, Izzo T, et al. Autologous stem cell transplantation for patients with acute promyelocytic leukemia in second molecular remission. Anticancer Res 2010;30:3845-3849.

18. Montesinos P, Díaz-Mediavilla J, Debén G, Prates V, et al. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica 2009;94:1242-1249.

19. Nagai S, Nannya Y, Arai S, Yoshiki Y, et al. Molecular or cytogenetic monitoring and preemptive therapy for central nervous system relapse of acute promyelocytic leukemia. Haematologica 2010;95:169-171.

20. Breccia M, Carmosino I, Diverio D, et al. Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count. Br J Haematol 2003;120:266-270.

21. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999;94:1192-1200.